Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis
Jette B Kornum1, Rikke B Nielsen1, Lars Pedersen1, Preben B Mortensen2, Mette Nørgaard1
1Department of Clinical Epidemiology, Aarhus University Hospital, Denmark; 2National Center for Registry-based Research, University of Aarhus, Aarhus, Denmark
Background: Data on the safety of selective serotonin-reuptake inhibitors (SSRIs) in pregnancy are inconsistent. We examined associations between SSRI use during early pregnancy and risk of congenital malformations in infants.
Methods: Set in Northern Denmark, our population-based prevalence study included 216,042 women who had a live birth after the 20th week of gestation. We compared the prevalence of malformation in infants born to women who redeemed at least one SSRI prescription during early pregnancy with the prevalence in infants born to women who redeemed no SSRI prescriptions during their pregnancies. Drug use data were extracted from prescription databases, while data on congenital malformations were obtained from the National Registry of Patients.
Results: The 2,062 women with SSRI prescriptions during early pregnancy gave birth to 105 (5.1%) infants with malformations, while the 213,712 women with no SSRI prescriptions gave birth to 7,449 (3.5%) infants with malformations. SSRI use was associated with an increased risk of malformations overall (odds ratio [OR] = 1.3; 95% confidence interval (CI): 1.1–1.6) and cardiac malformations (OR = 1.7; 95% CI: 1.1–2.5). For specific SSRIs, we found an increased risk for septal defects associated with sertraline.
Conclusions: We found little overall association between use of SSRIs during pregnancy and congenital malformations, but our findings suggest an association between maternal SSRI use in early pregnancy and cardiac malformations which could be causal.
Keywords: antidepressants, drug safety, pregnancy, congenital malformations, epidemiology
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H
Published Date: 23 July 2015
Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature
Cui QY, Shen HS, Wu TQ, Chen HF, Yu ZQ, Wang ZY
Published Date: 24 April 2015
Physical exercise and functional fitness in independently living vs institutionalized elderly women: a comparison of 60- to 79-year-old city dwellers
Furtado HL, Sousa N, Simão R, Pereira FD, Vilaça-Alves J
Published Date: 24 April 2015
Published Date: 12 December 2014
Khair K, Holland M
Published Date: 6 May 2014
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Published Date: 6 August 2010
Pär I Johansson, Sisse R Ostrowski
Published Date: 29 June 2010
Published Date: 28 June 2010
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
Ampaiwan Chuansumrit, Pantep Angchaisuksiri, Nongnuch Sirachainan
Published Date: 30 March 2010